Age Related Macular Degeneration Clinical Trial
— SEIRAOfficial title:
A Phase I Study of the Inhibition of LFA-1 to Intercellular Adhesion Molecule-1 (ICAM-1) Using Subcutaneous Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)
NCT number | NCT00726466 |
Other study ID # | FVF4385s |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 1 |
First received | July 29, 2008 |
Last updated | July 6, 2015 |
Start date | March 2008 |
Efalizumab is an immunosuppressive recombinant humanized IgG1 monocolonal antibody (150 Kd)
that binds to human CD11a (1) and is used for the treatment of plaque psoriasis. Efalizumab
was derived from the humanization of the murine efalizuman monoclonal antibody MHM24, which
recognizes human and chimpanzee CD11a. Humanization of MHM24 was accomplished by grafting
the murine complementarity determining regions (hypervariable region) into consensus human
IgG1/ heavy and light chain sequences (Werther et al 1996). These same consensus human
immunoglobulin sequences have been successfully used in the humanization of other murine
antibodies, including those targeted to HER2 and IgE. Efalizumab inhibits the binding of
LFA-1 to intercellular adhesion molecule-1 (ICAM-1) thereby inhibiting the adhesion of
leukocytes to other cell types.
Ranibizumab is a recombinant, humanized, Fab fragment of a mouse monoclonal antibody
targeted against VEGF. As VEGF binds to cellular receptors, it stimulates angiogenesis and
vascular leakage. Blockade of VEGF by ranibizumab leads to reduced stimulation of cell
proliferation and permeability resulting in inhibition of angiogenesis and decreased
leakage. Ranibizumab intravitreal administration in neovascular AMD patients has been shown
to effectively reduce vascular leakage and growth of CNV and to stabilize or improve visual
function.
To further improve visual acuity, a combination therapy using efalizumab and ranibizumab is
proposed. Efalizumab could target the adhesion factors that precede angiogenesis and improve
the outcome for AMD patients in combination with the anti-VEGF agent, Ranibizumab.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Ability to provide written informed consent and comply with study assessments for the full duration of the study. - Demonstrate understanding of and ability to perform weekly self sub-cutaneous injections. - Subjects of either gender, Age > 50 years - Best corrected visual acuity in the study eye between 20/40 and 20/320. - Subfoveal choroidal neovascularization, secondary to age related macular degeneration. 6-10 anti-VEGF treatments allowed prior to enrollment. - Presence of subretinal fluid and/or cystoid retinal edema on OCT. - Presence of fibrosis, hemorrhage, serous pigment epithelial detachments, tear (rip) of the retinal pigment epithelium or other hypofluorescent lesions should not obscure greater than 50% of the CNV lesion. - Annual immunization completed at least 4-6 weeks prior to BSL. - Clear ocular media and adequate papillary dilation to permit good quality stereoscopic fundus photography - Ability to return for all study visits Exclusion Criteria: - Pregnancy (positive pregnancy test) or lactation. - Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. - Had prior treatment with Photodynamic Therapy (PDT). - Had treatment with anti-VEGF agents within 30 days prior to BSL. - Had treatment with Kenalog within 6 months prior to BSL. - Had treatment with Dexamethaosne within 30 days prior to BSL. - Had ocular surgery within the past 60 days in the study eye. - Concurrent use of more than two therapies for glaucoma. - Uncontrolled glaucoma in the study eye (defined as intraocular pressure >30 mm Hg despite treatment with anti-glaucoma medication). - Concurrent use of systemic anti-VEGF agents - Has active infection in the study eye. - Inability to obtain photographs to document CNV. - Has received investigational therapy within 60 days prior to study entry. - Patients with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. - Have a history of hypersensitivity to efalizumab or any of its components - Current or history of prior treatment of psoriasis with subcutaneous efalizumab within 6 months of study entry. - Have a history of ongoing uncontrolled serious bacterial, viral, fungal, or atypical mycobacterial infection. This includes diagnoses that required more than 2 weeks of therapy, such as endocarditis and osteomyelitis, which have been treated in the past 6 months. In addition, if the subject is currently receiving antibiotics, antivirals, or antifungals for an infection or for suppression or prophylaxis for any diagnosis. - Have a history of opportunistic infections (e.g. systemic fungal infections, parasites) - Have the presence or history of malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled. - Have a history of thrombocytopenia, clinically significant hemolytic anemia, or unexplained anemia. - Have a platelet count < 100,000 cells/uL - Has other conditions the investigator considers to be sound reasons for exclusion (e.g., lack of motivation, history of poor compliance, concomitant illnesses, personality disorder, mental condition, drug abuse, use of neuroleptics, physical or social condition predicting difficulty in long-term follow-up). - Patients receiving immunosuppressive agents (including but not limited to cyclosporine, methotrexate, azathioprine, mycophenolate mofetil and systemic steroids) are excluded from the screening visit until study completion - All acellular, live and live-attenuated vaccines are excluded from 14 days prior to the first dose of efalizumab until a minimum of 4 weeks after the last dose of efalizumab - Has an allergy to sodium fluorescein dye. - Inability to comply with study or follow-up procedures. |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Vitreous Retina Macula Consultants of New York | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Vitreous -Retina- Macula Consultants of New York | Genentech, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | • Safety and tolerability of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in the treatment of age-related macular degeneration using the incidence and severity of adverse events through Month 6. | |||
Secondary | The secondary outcomes of this study are as follows: • Mean change in ETDRS BCVA at Months 6 and 12. • Mean change in central retinal thickness per OCT at Months 6 and 12 • Mean change in lesion and CNV size as determined by FA at Months 6 and 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |